CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We raised our 12-month target price by $10 to $245, reflecting a 27x multiple on our 2026 EPS estimate, a discount to BIO's three-year historical forward average of 29.5x. We lowered our 2026 EPS estimate to $9.09 from $9.17 and 2027 to $9.80 from $9.87. Though valuations improved somewhat following recent reports of a meaningful stake by activist investor Elliott Management, we think BIO and life sciences tools and services peers continue to navigate a difficult operating environment with pressures in key end markets such as biotech and government/academia. Following BIO's guidance during the Q1 earnings report, we anticipate flat to negative 0.5% sales growth in 2026, along with adjusted operating margin compression to 10.6% from 12.1%. BIO had total cash of $1.6B as of March 31, 2026, supporting the company's negative net debt position (cash exceeds debt).